Pharmacogenetic factors affecting β-blocker metabolism and response
CD Thomas, JA Johnson - Expert opinion on drug metabolism & …, 2020 - Taylor & Francis
CD Thomas, JA Johnson
Expert opinion on drug metabolism & toxicology, 2020•Taylor & FrancisIntroduction β-blockers are among the most widely prescribed of all drugs, used for
treatment of a large number of cardiovascular diseases. Herein we evaluate literature
pertaining to pharmacogenetics of β-blocker therapy, provide insight into the robustness of
the genetic associations, and determine the appropriateness for translating these genetic
associations into clinical practice. Areas covered A literature search was conducted using
PubMed to collate evidence on associations between CYP2D6, ADRB1, ADRB2, and GRK5 …
treatment of a large number of cardiovascular diseases. Herein we evaluate literature
pertaining to pharmacogenetics of β-blocker therapy, provide insight into the robustness of
the genetic associations, and determine the appropriateness for translating these genetic
associations into clinical practice. Areas covered A literature search was conducted using
PubMed to collate evidence on associations between CYP2D6, ADRB1, ADRB2, and GRK5 …
Introduction
β-blockers are among the most widely prescribed of all drugs, used for treatment of a large number of cardiovascular diseases. Herein we evaluate literature pertaining to pharmacogenetics of β-blocker therapy, provide insight into the robustness of the genetic associations, and determine the appropriateness for translating these genetic associations into clinical practice.
Areas covered
A literature search was conducted using PubMed to collate evidence on associations between CYP2D6, ADRB1, ADRB2, and GRK5 genetic variation and drug-response outcomes in the presence of β-blocker exposure. Pharmacokinetic, pharmacodynamic, and clinical outcomes studies were included if genotype data and β-blocker exposure were documented.
Expert opinion
Substantial data suggest that specific ADRB1 and GRK5 genotypes are associated with improved β-blocker efficacy and have potential for use to guide therapy decisions in the clinical setting. While the data do not justify ordering a CYP2D6 pharmacogenetic test, if CYP2D6 genotype is available in the electronic health record, there may be clinical utility for understanding dosing of β-blockers.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果